The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | Promising uses for PET/CT and MRI in clinical practice
Elena Zamagni, MD, PhD, from the Azienda Ospedaliero-Universitaria Policlinico S. Orsola, Malpighi, Bologna, Italy, discusses important papers recently published by the International Myeloma Working Group at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The first was regarding the use of novel imaging techniques, such as PET/CT or MRI, both in clinical trials and clinical practice. The second focused on the use of these novel techniques to assess for example bone marrow involvement, or disease metabolism to determine response to treatment, and the third discussed the use of these imaging techniques in prognosis.
